Literature DB >> 16331791

Scleroderma--developing measures of response.

Daniel E Furst1, Dinesh Khanna, Marco Mattucci-Cerinic, Alan J Silman, Peter A Merkel, Ivan Foeldvari.   

Abstract

The scleroderma research community continued its focus on the development and proper validation of the outcome measures for clinical trials in scleroderma during the special interest group meeting at OMERACT 7. Deliberations focused on progress in the assessment of gastrointestinal disease, renal physiology, vascular damage, and the unique challenges inherent in studying pediatric patients with scleroderma.

Entities:  

Mesh：

Year:  2005        PMID： 16331791

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  8 in total

1.  Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.

Authors:  P A Merkel; N P Silliman; P J Clements; C P Denton; D E Furst; M D Mayes; J E Pope; R P Polisson; J B Streisand; J R Seibold
Journal:  Arthritis Rheum       Date:  2012-10

2.  Development of a provisional core set of response measures for clinical trials of systemic sclerosis.

Authors:  D Khanna; D J Lovell; E Giannini; P J Clements; P A Merkel; J R Seibold; M Matucci-Cerinic; C P Denton; M D Mayes; V D Steen; J Varga; D E Furst
Journal:  Ann Rheum Dis       Date:  2007-09-24       Impact factor: 19.103

3.  Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique.

Authors:  Raymond S Douglas; Angelo Tsirbas; Mark Gordon; Diana Lee; Nicole Khadavi; Helene Chokron Garneau; Robert A Goldberg; Kenneth Cahill; Peter J Dolman; Victor Elner; Steve Feldon; Mark Lucarelli; Jimmy Uddin; Michael Kazim; Terry J Smith; Dinesh Khanna
Journal:  Arch Ophthalmol       Date:  2009-09

Review 4.  Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards.

Authors:  Dinesh Khanna; Daniel E Furst; Yannick Allanore; Sangmee Bae; Vijay Bodukam; Philip J Clements; Maurizio Cutolo; Laszlo Czirjak; Christopher P Denton; Oliver Distler; Ulrich A Walker; Marco Matucci-Cerinic; Ulf Müller-Ladner; James R Seibold; Manjit Singh; Alan Tyndall
Journal:  Rheumatology (Oxford)       Date:  2014-08-13       Impact factor: 7.580

Review 5.  Biomarkers in systemic sclerosis.

Authors:  Susan V Castro; Sergio A Jimenez
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

Review 6.  [The significance of health-related quality of life in systemic vasculitides].

Authors:  K Herlyn; F Moosig; W L Gross
Journal:  Z Rheumatol       Date:  2010-05       Impact factor: 1.372

7.  The symptom burden index: development and initial findings from use with patients with systemic sclerosis.

Authors:  Michael A Kallen; Maureen D Mayes; Yana L Kriseman; Sofia B de Achaval; Vanessa L Cox; Maria E Suarez-Almazor
Journal:  J Rheumatol       Date:  2010-06-01       Impact factor: 4.666

Review 8.  Outcome measures in systemic sclerosis: an update on instruments and current research.

Authors:  Dinesh Khanna; Peter A Merkel
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.